



Research Article

**A CLINICAL EVALUATION OF JATIPHALA CHURNA LEPA IN VYANGA WSR TO MELASMA**

**Rajashree Debbarma<sup>1\*</sup>, Raghunath.G.V<sup>2</sup>, Binu.M.B<sup>3</sup>**

<sup>1</sup>PG Scholar, <sup>2</sup>Professor & HOD, Dept. of Dravya Guna, Ramakrishna Ayurvedic Medical College Hospital & Research Centre, Bengaluru, Karnataka, India.

<sup>3</sup>PG Scholar, Dept. of Rasashastra and Bhaishajya Kalpana, Ramakrishna Ayurvedic Medical College Hospital & Research Centre, Bengaluru, Karnataka, India.

**ABSTRACT**

*Vyanga* is the one of the *Kshudra Roga*, characterised by *Niruja* (painless), *Shyava Varna Mandalas* (bluish black patches) occurring especially on the face. While considering the pathogenesis of *Vyanga*, involvement of *Pitta* is more and it is *Rakta Pradoshaja vyadhi*. On the basis of clinical features it is correlated with melasma, or facial melanosis, one of the hyper pigmented disorders. Melasma is a common acquired hypermelanosis that affects sun- exposed areas of skin. This study is important since melasma is a disease causing mental side effects in patients, due to darkness and opacity of the skin; therefore, the treatment of melasma in terms of its psychological complication is of particular importance. *Jatiphala* (*Myristica fragrans* Houtt.) is an important drug which has got various medicinal uses. The seed and aril of *Jatiphala* (*Myristica fragrans* Houtt.) of family myristicaceae have the utilized therapeutically as medicine as well as a spice. *Acharya Bhavamishra* have mentioned *Jatiphala* (*Myristica fragrans* Houtt.) as a single herbal remedy for its action on *Vyanga*.

**Intervention and duration:** 30 patients having hyperpigmentation on face with clinical manifestations, fulfilling the diagnostic criteria of *Vyanga*, the prepared *Lepa churna* was applied over the affected area, once a day for 60 days. Pre test assessment was done on 15<sup>th</sup> day, 30<sup>th</sup> and 60<sup>th</sup> day. **Results:** The subjective and objective parameters of the study were graded and the results of the study were analysed statistically using descriptive statistics where the study has shown statistically significant in the subjective and objective parameters. **Conclusion:** This clinical study of *Jatiphala churna lepa* showed the result in 50-60% of people in the group of *Vyanga*.

**KEYWORDS:** *Jatiphala*, *Vyanga*, Melasma, *Jatiphalachoorna lepa*.

**INTRODUCTION**

'Face is the index of mind'. The clean and clear face plays important role in the individual's personal, emotional, and social well-being. Acquired hyperpigmentation disorders of the skin are among the most common complaint in a general dermatology clinic<sup>[1]</sup>. Melasma is a common pigmentary disorder. It is a form of acquired hypermelanosis and occurs in sun exposed parts. It develops mostly on the face but occasionally it can also develop on the neck. Rarely, it can also appear on the forearms as well. Melasma is resistant to treatment and often causes significant psychological impact on the patient. It affects both males and females but predominantly seen in females<sup>[2]</sup>.

Hyperpigmentation (melanosis) is a group of disorders characterized by abnormally darker skin that results from increase in the concentration of

pigment, which occurs either due to increase the number of melanocytes or increase activity of melanocytes<sup>[3]</sup>. Melanosis most commonly results from exposure to sunlight, due to air pollution, different cosmetic using habits, stressful life, dietary changes, inclination towards junk or fast food<sup>3</sup>. Nowadays *Vyanga* becomes one of the biggest problems of the society. Many people are suffering from *Vyanga* today. Among them women are commonly found due to changes occurring during pregnancy and use of cosmetic supplements<sup>[4]</sup>.

In Ayurveda skin diseases are included under the heading of *Kustha* and *Kshudra roga*<sup>[4]</sup>. *Acharya Sushruta* was the first person who has given a detail and separate description of the disease *Vyanga* in the chapter of '*Kshudra Roga*'. *Vyanga* is a pathological situation of the facial skin which is produced due to

the vitiation of *Vata*, *Pitta* and *Rakta* producing cardinal features such as *Niruja*, *Tanu*, *Shyava Mandala* [5].

In the context of *Vyanga* both *Shodana* and *Shamana Chikitsa* are explained in the form of *Raktamokshana*, *Lepa*, *Abhyanga*, and oral medication [6]. As the disease has local spread over the skin of the face, the local or external applications have immediate impact upon the characteristics features of the *Vyanga*, such as discoloration, dryness on the face, burning sensations, itching etc.

*Alepa* being mentioned under *Bahyaupachaara* and for correcting *Bhrajakapitta* located in the skin, absorbs the drug into the body through skin [7].

*Acharya charaka* has broadly classified *chikitsa* under three main headings, namely *Antah Patimarjana*, *Bahir Parimarjana*, and *Shastra Prranidhana*. *Lepa kalpana* is the *Upakalpana*, which comes under *Bahir Parimarjana Chikitsa* [8].

The *Lepa* which is applied on the face gives strength to the muscle of eyes, cheeks has to be thick which enhance face complexion which in turns cures *Vyanga*. *Alepa* normalizes *Rakta* and *Pitta* [9].

So, the *Lepa* which is one of the forms of external application for skin diseases is taken for this study.

*Jatiphalaadi Choorna Lepa* is a formulation mentioned in *Bhavaprakasha*. *Jatiphala* (*Myristica fragrans* Houtt.) it has properties like *Katu Tikta Rasa*, *Laghu Tikshna Guna*, *Ushna Virya*, *Katu Vipaka*, *Vatakapha hara*, *Varnya*, *Dipana*, *Grahi* in action. Classics say that the fine powder of these drug, made into paste using water and applied over the *Mukha Pradesha*, relieves *Vyanga* [10].

In *Jatiphala myristicin* present, is known to be useful in reducing the production of melanin secretion in skin. It also has antioxidant properties which act on free radicals. It was also observed that *Jatiphala* have got exfoliating property, which help in formation of new fresh healthy skin removing unhealthy layer [11].

Hence the present study was undertaken to evaluate the efficacy of *Jatiphalaadi choorna Lepa* in the management of *Vyanga* with special reference to melasma on face with the hope of quicker action.

## MATERIALS AND METHODS

### Phase 1: Collection and preparation of *Jatiphala churna*

Phase 2: Clinical studies.

### Source of Data

**Literary source:** The literary data was collected from classical *Ayurvedic* texts, modern text books,

*Samhitas*, *Nighantus*, websites, articles and various journals.

**Source of drugs:** Botanically identified drug of *Jatiphala* (*Myristica fragrans* Houtt.) was collected from its natural habitat. The test drug was prepared from *Rasa Shastra & Bhaishajya kalpana* department *Rasashala* of *Ramakrishna Ayurvedic Medical College*, *Yelahanka*, *Bangalore*.

**Source of patients:** patients who attended OPD of *RAMC hospital*, *medical camps* and other referrals with the compliance of macular brownish/blackish discoloration over the face, nose, forehead, upper lip with the diagnosis of *Vyanga* or *melasma* were selected fulfilling the inclusion and exclusion criteria.

### Selection of patients

Patients suffering from signs and symptoms of *Vyanga roga* were selected from OPD of *RAMCH*, *Bengaluru*, *Medical camps*, and other reference irrespective of their sex, religion, occupation etc. Detailed history was taken and a special research proforma was prepared for the study incorporating all the relevant points from both *Ayurvedic* and *Modern views*.

### Study design

It is an open label single arm clinical study. 30 patients will be selected from random sampling procedure.

**Sample size:** A total of 30 patients were studied.

**Dosage:** Quantity sufficient

### Plan of treatment

Patients were apply the paste of *Jatiphala churna* with water over affected area for 60 days with the thickness of  $\frac{1}{2}$  *Angula* once in a day.

**Duration:** The duration of the study was 60 days.

**Follow up:** Follow up was done at an interval of 15 days up to 2months.

### Inclusion criteria

- Patients from the age group 26-60. (of either gender, religion, occupation, socio- economic status).
- Patient representing signs and symptoms of *Hypermelanosis (Vyanga)* who were willing to participate in study.

### Exclusion criteria

- Patients having systemic and endocrinal diseases, like *Addison's diseases*, *Cushing's syndrome* etc.
- *Hyperpigmentation* since birth.
- *Hyperpigmentation* caused by tumor like *malignant melanoma*.
- Patients with drug induced *chloasma*.
- Patients who were not willing to participate.

**Ethical consideration**

Ethical clearance was obtained from the institutional ethical committee of Ramakrishna Ayurvedic Medical College and Hospital, Yelahanka, Bengaluru.

**Criteria of withdrawal**

- Increase symptoms like redness of the skin, *Kandu* (itching), and excessive burning sensation.
- Patients who are not willing to continue.

**Diagnostic criteria**

Patients are diagnosed as per clinical features mentioned in classics.

1. *Niruja* – painless patches.
2. *Tanu* – light brown pigmentation on facial skin.
3. *Shyava* – dark brown pigmentation on facial skin.

**Objective parameter****Table1: Objective parameter size**

Size	Score
0-1 cm	1
1-3 cm	2
3-6 cm	3
>6 cm	4

**Table 2: Objective parameter colour**

Colour	Score
Very fair	1
Fair	2
Medium	3
Olive	4
Brown	5
Dark brown	6

Standard graded scale (Fitzpatrick scale) is used to assess the change in colour of the skin in affected area before and after treatment.

**Assessment schedule**

Assessment of was done as per following schedule: 1<sup>st</sup> assessment- 1<sup>st</sup> day (before treatment)

2<sup>nd</sup> assessment- 15<sup>th</sup> day (during treatment) 3<sup>rd</sup> assessment- 30<sup>th</sup> day (during treatment) 4<sup>th</sup> assessment- 60<sup>th</sup> day (after treatment) Likewise, data was collected of all the 30 patients.

**Assessment chart****Table 3: Subjective Parameter**

Sl no	Parameter	Before treatment	Review after 30 days	After treatment (60 days)
1.	<i>Neerujam</i>	Yes/no	Yes/no	Yes/no
2.	<i>Shyavam</i>	Yes/no	Yes/no	Yes/no
3.	<i>Tanu</i>	Yes/no	Yes/no	Yes/no
4.	<i>Mukhamaagatya mandala</i>	Yes/no	Yes/no	Yes/no

4. *Mukhamaagatya mandala* – patches over face.

**Assessment criteria**

The subjective and objective parameter of baseline data to pre and post medication was compared for assessment of the results.

**Subjective parameter**

The signs and symptoms of *Vyanga* as well as Hypermelanosis explained in Ayurvedic and Modern texts will be subjective parameters.

1. *Neerujam* (painless lesion)
2. *Shyavam* (brownish pigmentation)
3. *Tanu* (light pigmentation)
4. *Mukhamaagatya Mandala* (hyperpigmented patch over face).

**Observation and Result****Table 4: Objective Parameter**

Sl no	Parameter	Score		
		Before treatment	Review after 30 days	After treatment 60 Days
1.	Size	1.00-3.00	0.00-2.00	0.00-2.00
2.	Colour	2.00-6.00	1.00-5.00	1.00-5.00

**Result assessment:**

Finally over all result was calculated by taking average of all parameter results.

**Statistical methods**

Descriptive and inferential statistical analysis has been carried out in the present study. Results on continuous measurements are presented on Mean SD (Min-Max) and results on categorical measurements are presented in Number (%). Significance is assessed at 5 % level of significance. The following assumption on data is made.

**Observation and Results**

The study was conducted to evaluate the efficacy of *Jatiphala choorna* on *Vyanga* wsr to Melasma. A total of 30 patients were selected randomly for the intended study. All the patients were assessed before and after treatment for the grading of their subjective and objective parameters. The observations and results are presented as follows.

**Study design:** An observational clinical study.

**Table 5: Age distribution of patients studied**

Age in years	No. of patients	%
<30	3	10.0
30-40	10	33.3
41-50	12	40.0
51-60	5	16.7
Total	30	100.0

Mean  $\pm$  SD: 41.67 $\pm$ 8.69

In the age wise distribution of the patients it was observed maximum of 12 (40%) were under the age group of 41-50 years, 10 (33.3%) were under the age group of 30-40 years, 5 (16.7%) were under the age group of 51-60 years and 3 (10%) were under the age group of 16-30 yrs.

**Table 6: Gender distribution of patients studied**

Gender	No. of patients	%
Male	3	10.0
Female	27	90.0
Total	30	100.0

In the present study among the 30 subjects, 27 (90%) were female and 3 (10%) were male.

**Table 7: Religion distribution in patients studied**

Religion	No. of patients	%
Hindu	14	46.7
Muslim	8	26.7
Christian	8	26.7
Total	30	100.0

In the present study among 30 subjects, a maximum of 14 (46.7%) belong to Hindu religion, 8 (26.7%) belonged to Christian and 8 (26.7%) belonged to Muslim religion.

**Table 8: Education distribution in patients studied**

Education	No. of patients	%
Illiterate	7	23.3
Elementary education	7	23.3
Higher secondary	5	16.7
Graduate	9	30.0
Post graduate	2	6.7
Total	30	100.0

In the present study, it was observed that 7 subjects (23.3%) were Illiterate, 7 (23.3%) had elementary education, 5 (16.7%) had higher secondary education, 9 (30%) were graduates and 2 (6.7%) were post graduate.

**Table no 9: Marital Status distribution in patients studied**

Marital Status	No. of patients	%
Unmarried	1	3.3
Married	29	96.7
Total	30	100.0

In this study among 30 subjects, 29 (96.7%) were married and 1 (3.3%) were unmarried.

**Table no 10: Occupation distribution in patients studied**

Occupation	No. of patients	%
Field work	2	6.7
Office work	8	26.7
House work	11	36.7
Agriculture	5	16.7
Student	1	3.3
Teacher	3	10.0
Total	30	100.0

In the present study among 30 subjects 11 (36.7%) were House makers, 8 (26.7%) were Office Workers, 5 (16.7%) were Agriculturist, 3 (10%) were Teachers, 2 (6.7%) were Field workers and 1 (3.3%) was a Student.

**Table 11: Habitat distribution in patients studied**

Habitat	No. of patients	%
Urban	15	50.0
Rural	15	50.0
Total	30	100.0

In the present study it was observed that maximum subjects i.e. 15 (50%) belong to Urban locality and 15 (50%) were from Rural locality.

**Table no 12: Diet pattern distribution in patients studied**

Diet	No. of patients	%
Veg	8	26.7
Mixed	22	73.3
Total	30	100.0

In this study, 22 (73.3%) subjects were used to mixed diet and 8 (26.7%) subjects were vegetarians.

**Table 13: Prakruthi distribution in patients studied**

Prakruthi	No. of patients	%
Vataja pittaja	14	46.7
Vata kaphaja	6	20.0
Kapha pittaja	10	33.3
Total	30	100.0

In this study, 14 (46.7%) subjects are having *Vata pittaja prakruthi*, 10 (33.3%) are having *Kapha pittaja prakruthi*, and 6 (20%) are having *Vata kaphaja prakruthi*.

**Table 14: Onset of disease distribution in patients studied**

Onset	No. of patients	%
Gradual	30	100.0
Sudden	0	0.0
Total	30	100.0

In this study, the observation regarding the mode of onset of *Vyanga* in individual subjects in this study that majority of them 30 (100%) had gradual and 0% had insidious onset.

**Table 14: Previous Treatment distribution in patients studied**

Previous Treatment	No. of patients	%
Fresh	25	83.3
Treated	5	16.7
Total	30	100.0

In this study 25 subjects (83.3%) approached the hospital for the first time to take treatment and 5 (16.7%) had already taken different forms of treatment of different systems of varying duration.

**Effects on Treatment**

**Objective Parameters**

**Table 15: Size- An assessment at before and after treatment of patients studied**

Size	Before Treatment	30 days	After Treatment	% difference
0-1cm	0 (0%)	3 (10%)	11 (36.7%)	36.7%
1-3cm	4 (13.3%)	18 (60%)	16 (53.3%)	40.0%
3-6cm	19 (63.3%)	9 (30%)	3 (10%)	-53.3%
>6cm	7 (23.3%)	0 (0%)	0 (0%)	-23.3%
Total	30 (100%)	30 (100%)	30 (100%)	-

Improvement of 76.7% up to 3 cm after treatment is significant with  $P < 0.001^{**}$ , paired proportion test

**Table 16: Colour - An assessment at before and after treatment of patients studied**

Colour	Before Treatment	30 days	After Treatment	% difference	P value
Very fair	0 (0%)	1 (3.3%)	4 (13.3%)	13.3%	0.020*
Fair	1 (3.3%)	3 (10%)	4 (13.3%)	10.0%	0.088+
Medium	3 (10%)	6 (20%)	11 (36.7%)	26.7%	0.013*
Olive	6 (20%)	9 (30%)	10 (33.3%)	13.3%	0.220
Brown	9 (30%)	11 (36.7%)	1 (3.3%)	-26.7%	0.004**
Dark brown	11 (36.7%)	0 (0%)	0 (0%)	-36.7%	0.0004**
Total	30 (100%)	30 (100%)	30 (100%)	-	

**Table 17: Size-An assessment at before and after treatment of patients studied**

Size	Min-Max	Mean ± SD	difference	t value	P value
Before Treatment	1.00-3.00	2.10±0.61	-	-	-
30days	0.00-2.00	1.20±0.61	0.900	16.155	<0.001**
After Treatment	0.00-2.00	0.73±0.64	1.367	12.173	<0.001**

**Table 18: Over All Assessment**

Parameter	Mean BT	Mean AT	% of Improvement	Remarks
Size	2.10	0.73	65.2	Marked improvement
Colour	4.87	3.00	38.30	Moderate improvement

It was seen that trial drug worked better in improving the size of the lesion with 65.2% improvement (marked improvement) and showed 38.3% improvement i.e. moderate improvement in colour.

## DISCUSSION

### Discussion on selection on problem

Melasma or hyper pigmentation is the one among the top five leading conditions in Asia. Ethnicity, genetic factors, and sun exposure play important roles. The accurate prevalence of melasma world wide is unknown. This is attributed to the fact that melasma is a cosmetic problem and most patients may choose to consult their dermatologist privately. Hence, a low prevalence of melasma is recorded in most public dermatology clinics. Although melasma affects all races, it is most prevalent among darker skin phototypes and mainly found in patients of Hispanic, Latin Americans, Asians, Middle eastern and Africans descent.

Melasma affects women more than men and occurs during child bearing age. Melasma occurs 10-15% of pregnant women, 10-25% of women taking oral contraceptives. The major etiological factors include genetic influences, chronic sun exposure and female sex hormones.

Ayurveda explains *Vyanga* as a disease which is mainly characterized by dark discolouration of the skin over face. It is a pathological situation of the facial skin which is produced due to the vitiation of *Vata*, *Pitta*, and *Rakta* producing cardinal features such as *Niruja*, *Tanu*, *Shyava Mandala*.

### Discussion on procedure

*Jatiphala* seed was taken and it was pounded into small pieces using *Khalva yantra* and then it was put into pulveriser and powdered and it was packed into small zip lock airtight poly bags of about 30 gm each. Dose of the drug was not fixed depend on the area of the patches on the face.

### Probable mode of action

The *Katu Tikta Kashaya Rasa* of *Jatiphala* tackles *Srodusthi* caused by *Agnisada* (which forms *Ama* and leads to *Srotodusthi*). The *Tikta Rasa* of *Jatiphala* causes *Pitta Samaka* which is vitiated due to intake of *Pitta Ahara Dravyas*.

Since the disease *Vyanga* is considered the disease of disturbed *Bhrajaka Pitta*, *Rasa*, *Rakta Vaha Sroto Dusti*, *Vata* and *Pitta Prakopa* also involving *Kapha* which obstructs *Rasavaha Srotas* leading to *Syavatwam* of the skin by causing the *Prakopita Bhrajaka Pitta* to be deposited below the skin layers that is in epidermis.

*Tikta Rasa Usna Virya* of *Jatiphala* mitigates *Vata Dosa* and the same time it stimulates *Bhrajaka Pitta* and help in scraping of the rough, thick, black dark layers formed on the skin.

The *Laghu Guna*, *Tikshna Guna* and *Ushna Virya* properties along with *Katu Rasa* clears the channels helping the healthy *Bhrajaka Pitta* and opens the free movement of *Bhrajaka Pitta* on to the skin. *Bhrajaka Pitta* is responsible for *Varna*, *Chayya*, and *Prabha*. In *Ashtanga Hridaya sutra sthana* 12<sup>th</sup> chapter mentioned that *Pitta* located in the skin in *Bhrajaka*, because it helps exhibition of colour and complexion.

*Prabha* and *Chayya* also effect on *Varna*. *Acharya Charaka* has written that *Prabha* is said to be highlighter of complexion.

Myristicin present in *Jatiphala* is known to be useful in reducing the production of melanin secretion in skin. It also has antioxidant properties which act on free radicals.

It was also observed that *Jatiphala* have got exfoliating property, which help in information of new fresh healthy skin removing unhealthy layer.

Discussion on clinical study:

- The clinical study was carried out on 30patients.
- The type of skin lesion here in all subjects generally is Macule, as there is only discoloration, no pain, no discharge, no swelling.
- Patients were asked to apply the *Lepa* triturated with water only, as it was clearly mentioned in *Dipika* commentary of *Sharangadhara Samhita*.

- Patients experienced slight burning sensation for about 5-10 minutes during the time of application of *Lepa*, this is due to the acidic nature of the *Lepa*.
- There were no adverse effects or any other side effects like rashes, redness, itching etc observed during the time of application of *Lepa*.
- Patients were asked not to get exposed to excessive sunlight during the one month of treatment as it leads to further *Vata* and *Pitta Prakopa*.
- Thickness of *Lepa* should be *Ardha Angula* (which is approximately 0.88cm) as it is difficult to measure the thickness of the *Lepa*, patient was asked to apply the *Lepa* as thick as possible.
- As seat of *Vyangais* in the 2<sup>nd</sup> layer of skin, that is *Lohita* according to *Susrutha* and *Asrukdhara* according to *Charaka*, the thickness of *Lepa* is such that it penetrates the second layer of the skin.

#### Discussion on observations of clinical study

The observations made in the present study were based on the clinical study conducted in a single group on 30 subjects. The data was collected in the proforma and analyzed after the completion of the study.

#### Age

In the present study among 30 subjects who completed the clinical trial, a maximum of 10 (33.3%) were under the age of 30-40 years, 3 (10%) were under the age group 16-30 years and 12 (40.0%) were under the age group of 41-50 years and 5 (16.7%) was under the age group of 51-60 years.

Hence, the inference can be drawn that the prevalence of *Vyanga* is more in middle aged people or *Madhyama vayah*. *Vyanga* is caused mainly due to *Vata* and *Pitta Prakopa* as *Pitta Dosha* is *Prakupita* in *Madhyama Vayah*, *Vyanga* is more prevalent in middle age.

#### Gender

In the present study among the 30 subjects, maximum of 27 (90%) were female and 3 (10%) were male.

Among 27 female subjects, majority of them are workers and home makers having history of more sun exposure and stress/worry. Majority of them have acquired *Vyanga* post pregnancy, thus the prevalence in females may be attributed to post pregnancy sun exposure and stress/worry.

#### Occupation

In the present study, among 30 subjects 2 (6.7%) were field workers, 11 (36.7%) were house makers, 1 (3.3%) were students and 3 (10%) were

teachers, 8 (26.7%) was office work or businessman, 5 (16.7 %) were agriculture.

In all the above occupations people are exposed to sunlight and ultra violet rays. This attributes to the fact that *Vyanga* is prevalent more in the people who are more exposed to sunlight.

#### Habitat

In the present study, it was observed the maximum subjects i.e. 15 (50%) belong to urban locality and 15 (50%) were from rural locality. However no conclusion can be drawn, because of the small sample size.

#### Deha prakruthi

In the study, 14 (46.7%) subjects are having *Vata Pittaja Prakruti*, 10 (33.3%) subjects, are having *Kapha Pittaja Prakruthi*, 6 (20%) subjects are having *Vata Kaphaja Prakruti*.

This attributes to the fact that *Vyanga* is more seen in people with *Vata Pittaja Prakruti*.

#### Fresh/Treated

In this study, 25 subjects (83.3%) approached the hospital for the first time to take treatment and 5 (16.7%) had already taken different forms of treatment of different systems of varying duration.

This indicates recurrent/episodic nature of the disease and lack of permanent treatment for *Vyanga* in other systems of medicine which requires early management.

#### Family history of Vyanga

In the present study among 30 subjects, family history of *Vyanga* with special reference to hyper pigmentation on face was totally absent, which is shows that there is no involvement of genetic factors.

#### Religion, Educational Status, Diet

No significant relationship can be drawn in the above parameters in relation to *Vyanga* with special reference to hyper pigmentation on face.

#### Discussion on results of clinical study

In the present study the results of subjective parameters which were assessed such as colour of the patch area and size of the patch area showed statistically highly significant reduction with the p value less than 0.05.

This can be attributed chiefly to the *Varnya*, *Vatapitta Shamaka*, *Kapha Pitta Shamaka*, *Sheeta Veerya*, *Katu Vipaka*, cooling, disinfectant and blood purifying anti-inflammatory properties of the drugs present in the intervention, decreases about *Vata* and *Pitta* in the *Twacha* and enhances *Varna* of *Twacha*. Therefore the pathological disintegration –

*Niruja, Shyava, Tanu, Mukhamandala* i.e. size and colour of the patch area gets decreased.

The decreased in the mean suggests significant reduction in the *Vyanga*. It also indicates that after each day of intervention the severity of the condition is getting relieved, which can be attributed to the *Varnya, Vata Pitta Shamaka, Kapha Pitta Shamaka, Sheeta Veerya, Katu Vipaka*, cooling, disinfectant and blood purifying anti-inflammatory properties of the drugs present in the intervention.

Hence, it was inferred that the intervention selected for the present study has shown combined effect in the management of *Vyanga* vis-a-vis hyper pigmentation on face.

## CONCLUSION

On the basis of reviews collected, analysis of analytical study, results and observations on the clinical study, the following conclusions may be drawn.

*Acharya Bhavamishra* clearly mentioned *Jatiphala* as a single herbal remedy for its action on *Vyanga*. The *Katu, Tikta Rasa* of *Jatiphala* removes *Srodusti* thereby helping free movement of healthy *Bhrajaka Pitta* to the skin. *Tikta Rasa* and *Usna Virya* of *Jatiphala* prevent *Vata Dosha* thereby reducing *Kharatwa* and *Krishnatwa* of skin.

The *Snigdha, Soumya, Sita, and Twak Prasadana* properties along with *Rasayana* property help in reducing *Vyanga* and skin in more permeable to lipids than aqueous solution. The *Lepa* procedure helps in micro absorption and improves micro circulation of chemical constituents of drugs due to the disintegration of drug particles into the finest form.

The chemical compound 'Myristicin' present in it may help to reduce the production of melanin in skin.

## REFERENCES

1. G.Pallavi, K.L Virupaksha gupta, M. Shreevasta, vasudev A. Chate, D.L.Balakrishna - clinical evaluation of *Varnya gana lepa invyanga* (melasma), *AYU*. 2015 Apr-Jun; 36(2): 151-156.
2. Amit G Pandya, Susan C taylor - text book of

*Melasma A Monograph*, 2<sup>nd</sup> edition, editor Rashmi sarkar, New Delhi, 2018, chapter no-4, page no-20.

3. API textbook of Medicine- 7<sup>th</sup> edition Revised Reprint by Siddharth N Shah. Page no-273 &274.
4. Dr.Sreelatha.R. A Randomized comparative clinical study to evaluate the effect of topical formulations in *Vyanga* (chloasma) 2011- 2012, pageno:1-2.
5. Sushrutha, *Sushrutha Samhita with Ayurveda Tatvasandipika of Ambikadutta Shastri*, edited by Yadavji Trikamji Acharya. Varanasi Chaukamba Sanskrit Sansthana 2007; *Nidana sthana*, chapter 13, sloka no 9,pg:288.
6. Dr.Sreelatha.R. A Randomized comparative clinical study to evaluate the effect of topical formulations in *Vyanga* (chloasma) 2011- 2012, pg:2.
7. Yasmin S, Dixit Renu and Reddy K.V.V Bhaskara- Clinical and comparative study of *Jatiphala* and *Javitri* in Hyperpigmentation, *World Journal of Pharmaceutical Research*. 2016, vol 6, issue 1, 598-630.
8. Agnivesha, *Charaka samhita with Ayurveda Deepika teeka of Chakrapanidatta*, edited by Yadavji Trikamji Acharya. Varanasi Chaukambha Sanskrit sansthan; 2004, pg-58, 78, 116, 120, 595,768.
9. Yasmin S, Dixit Renu and Reddy K.V.V Bhaskara- Clinical and comparative study of *Jatiphala* and *Javitri* in Hyperpigmentation, *World Journal of Pharmaceutical Research*. 2016, vol 6, issue 1, 598-630.
10. Bhavamishra, Bhavaprakasha translator K.Srikanthamurthy, Kriahnadas Academy, Varanasi, Chaukamba Surabharati Prakashan, reprint-2000, Vol- 2,6<sup>1st</sup> chapter, verse- 37,39,40,41, pg-657,658.
11. Yasmin S, Dixit Renu and Reddy K.V.V Bhaskara- Clinical and comparative study of *Jatiphala* and *Javitri* in Hyperpigmentation, *World Journal of Pharmaceutical Research*. 2016, vol 6, issue 1, 598-630.

### Cite this article as:

Rajashree Debbarma, Raghunath.G.V, Binu.M.B. A Clinical Evaluation of *Jatiphala Churna Lepa* in *Vyanga wsr to Melasma*. *International Journal of Ayurveda and Pharma Research*. 2020;8(Suppl 2):17-26.

**Source of support: Nil, Conflict of interest: None Declared**

### \*Address for correspondence

**Dr. Rajashree Debbarma**

Final year PG Scholar

Department of *Dravya Guna*

RAMCH & RC, Bengaluru

Karnataka, India.

Email: [dbrajashree@gmail.com](mailto:dbrajashree@gmail.com)

Mobile: +91 8884044514

Disclaimer: IJAPR is solely owned by Mahadev Publications - dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJAPR cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of IJAPR editor or editorial board members.

**IMAGES**



**Image 1: Jati plant**



**Image 2: Jatiphala**



**Image 3: Jatiphalabeeja**



**Image 4: Jatiphala beeja Choorna preparation**



**Image 5: Jatiphala beeja Choorna**